Halozyme Reports Second Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Halozyme Therapeutics (HALO) PT Raised to $66 at BMO Capital
August 10, 2021 9:04 AM EDTBMO Capital analyst Do Kim raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $66.00 (from $64.00) while maintaining an Outperform rating.
The analyst commented, "HALO reported 2Q21 royalty revenues of $45.8mn, ahead of our $40.9mn estimate and consensus' $45.4mn. 2021 guidance was also revised... More
Halozyme Therapeutics (HALO) Tops Q2 EPS by 26c; Raises Outlook
August 9, 2021 4:05 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.66, $0.26 better than the analyst estimate of $0.40. Revenue for the quarter came in at $136.5 million versus the consensus estimate of $103.16 million.
GUIDANCE:
Halozyme Therapeutics sees FY2021 EPS of $1.85-$2.00, versus the consensus of $1.41.... More
